Q1 Earnings Estimate for Illumina Issued By Leerink Partnrs

Illumina, Inc. (NASDAQ:ILMN) – Research analysts at Leerink Partnrs raised their Q1 2025 earnings estimates for shares of Illumina in a note issued to investors on Tuesday, January 7th. Leerink Partnrs analyst P. Souda now expects that the life sciences company will post earnings per share of $0.85 for the quarter, up from their prior estimate of $0.84. The consensus estimate for Illumina’s current full-year earnings is $4.11 per share.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.26. The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.33 earnings per share.

Other analysts also recently issued research reports about the stock. Morgan Stanley reissued an “equal weight” rating and issued a $156.00 price objective on shares of Illumina in a research note on Tuesday, November 12th. UBS Group raised their target price on shares of Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Piper Sandler reduced their target price on shares of Illumina from $195.00 to $185.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. Stephens raised their target price on shares of Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Finally, HSBC raised shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a research report on Thursday, October 17th. Eight research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Illumina has an average rating of “Moderate Buy” and an average target price of $165.95.

Illumina Stock Down 2.1 %

Shares of NASDAQ ILMN opened at $136.69 on Thursday. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The company has a market cap of $21.68 billion, a P/E ratio of -13.72 and a beta of 1.11. Illumina has a 1 year low of $100.08 and a 1 year high of $156.66. The firm has a 50-day simple moving average of $141.11 and a two-hundred day simple moving average of $132.27.

Institutional Investors Weigh In On Illumina

Several hedge funds have recently modified their holdings of ILMN. Versant Capital Management Inc boosted its stake in shares of Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 146 shares in the last quarter. TD Private Client Wealth LLC raised its position in shares of Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after purchasing an additional 141 shares during the last quarter. Massmutual Trust Co. FSB ADV raised its position in shares of Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after purchasing an additional 168 shares during the last quarter. Itau Unibanco Holding S.A. acquired a new position in shares of Illumina during the 2nd quarter worth about $61,000. Finally, Private Trust Co. NA raised its position in shares of Illumina by 81.2% during the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after purchasing an additional 212 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.